Scorpion Therapeutics is expanding the potential of precision medicine to cancer patients. Using their fully integrated discovery platform that uses cancer biology, medicinal chemistry, chemical proteomics and molecular biophysics, Scorpion is advancing drug discovery, small molecule design and target identification to rapidly create selective small molecule compounds against an unprecedented spectrum of targets. Scorpion is currently focusing on validated oncogene targets as well as undruggable targets and novel cancer targets. Their lead program, STX-478, is an oral inhibitor of PI3K-alpha that is in clinical stages as a monotherapy for patients with breast cancer.

Scorpion Therapeutics

Scorpion Therapeutics Presents Initial Clinical Data From Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024 - Business Wire


      
        




    01/13/2021

    

      
      J.P. Morgan 39th Annual Healthcare Conference
      Read More
    

 Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B 


      
        




    10/26/2020

    

      
      Scorpion Therapeutics Debuts With $108m To ‘put The Sting In Cancer’
      Read More
    

04/3/2023 Press Release Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer Read More

Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline - Fierce Biotech

10/26/2022 Press Release Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022 Read More

 Scorpion stinger bringer of more PI3Kα inhibitor deals? 

Today, we are one step closer to potentially improving the lives of patients living with non-small cell lung cancer (#NSCLC). We’re excited to announce that the first patient has been treated in a Phase 1/2 first-in-human dose-escalation, dose-optimization and dose-expansion trial of STX-241, a highly differentiated, orally bioavailable, highly selective tyrosine kinase inhibitor targeting EGFR Exon 19 or 21 mutations with the co-occurring C797S mutation. STX-241 was discovered by Scorpion and is the second program being developed in collaboration with Pierre Fabre Laboratories. 
Learn more: https://bit.ly/3Nf3PzB
 
#NSCLC #PrecisionOncology

At Scorpion, we're committed to giving back to our local communities and making a positive impact. Recently, our employees came together to build children's bikes for donation to East Boston Social Centers and the Redwood City Pal Center.

This community service event was more than just team building; it was about supporting local organizations and bringing joy to children in need. We're grateful to all the Scorpions who made this event a success. Let's continue to support and uplift our communities together. 

 Scorpion Therapeutics Raises $150M in Series C Financing 

Two local biotechs land $410M in investments as VC picks up - The Business Journals

Scorpion raises $150M with sights on the next wave of targeted therapies - Endpoints News

 New TP53 activators disclosed by Scorpion Therapeutics 

04/4/2022 Press Release Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. To Its Board Of Directors Read More

This Startup Raised $5.2 Million To Develop Blood Tests For Cancer - Forbes

OnKure hitches Reneo's ride to Nasdaq, with $65M PIPE to boot - Fierce Biotech

Lilly circles $2.5B Scorpion buy as pre-JPM rumour mill churns - FirstWord

Rx Rundown: Novartis, Goldman Sachs, Klick Health and more - MM+M Online

10/12/2022 Press Release Scorpion Therapeutics to Present Preclinical Proof-of-Concept Data for Highly Selective, Next-Generation Exon 20 Mutant EGFR Inhibitor at 34th EORTC-NCI-AACR Symposium Read More

 Scorpion Therapeutics Presents Preclinical Data for STX-241, a 

 Processes of preparing pi3k inhibitors 

 Scorpion Therapeutics describes new PI3Kα inhibitors 

Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478 - Business Wire

Watch Eli Lilly CEO on Fighting Cancer and Obesity, Pricing (Correct) - Bloomberg.com

 Compounds that inhibit the alpha isoform of pi3k and methods for treating … 

Lilly Acquires Breast Cancer Treatment Program from Scorpion Therapeutics in $2.5B Deal - Femtech Insider

Eli Lilly said to be in talks to buy Scorpion Therapeutics for $2.5B - breakingthenews.net

Pierre Fabre in $618m EGFR deal with Scorpion - BioProcess Insider

09/12/2022 Press Release Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer Read More

 Lilly (LLY) to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program 

Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline - Pulse 2.0

Sanofi's Michael Streit departs to be cancer-focused Scorpion's first CMO - Fierce Biotech

Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer - citybiz

01/5/2022 Press Release Scorpion Therapeutics Receives Biospace Nextgen Bio “class Of 2022” Recognition Read More

10/25/2021 Press Release Scorpion Therapeutics Expands Executive Leadership Team With Three Key Appointments Read More

Odyssey raises epic $101M to push programs off to clinical sea - Fierce Biotech

 Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer 

Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D. - Business Wire

Chutes & Ladders—New year, new CEO at Scorpion Therapeutics - Fierce Biotech

Scorpion secures $150m to progress oncology pipeline - Pharmaceutical Technology

 JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more 

New TP53 activators disclosed by Scorpion Therapeutics - BioWorld Online

 Scorpion Therapeutics Announces Discovery Scientific Advisory Board 

Lilly Drops Up To $2.5B for Scorpion’s PI3K-inhibitor Molecule - BioSpace

Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology - MedCity News

 The paradox of a thriving U.S. economy 

Scorpion Therapeutics debuts with $108M to 'put the sting in cancer' - Fierce Biotech

 Lilly’s ‘timely’ $2.5B Scorpion deal; GSK pays $1B up front for Idrx 

AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out of undruggable cancer targets - Fierce Biotech


      
        




    07/19/2022

    

      
      Axel Hoos Wants to Take Small Molecules Further at Scorpion, Leaving Big Pharma in the Dust
      Read More
    


      
        




    01/12/2021

    

      
      With Biotech Funding At ‘All-time High,’ Scorpion Scoops Up $162 Million
      Read More
    

Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B - dailyjournal.net

04/8/2022 Press Release Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022 Read More

Lilly Pays Up To $2.5bn For Scorpion, Will Put Big Pharma Muscle Behind PI3Kα Inhibitor - insights.citeline.com

Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets - Business Wire

07/7/2021 Press Release Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D. Read More

Today at #ESMO2024, we announced initial clinical data from our Phase 1/2 Trial of STX-478 demonstrating potentially best-in-class mutant-selective PI3Kα inhibition for the treatment of advanced solid tumors
Learn more: https://bit.ly/3MLH4CX 

 Ins & Outs: C-suite changes across biotechs - BioProcess Insider 

Advancing the future of precision oncology and making a difference in patients' lives has always been at the heart of our mission. As we close the chapter on Scorpion and pass the torch, we are proud to place our mutant-selective PI3Kα inhibitor program, STX-478, in the trusted hands of Lilly Oncology. We are filled with gratitude for the journey so far and look forward to seeing how this program continues to shape the future of cancer care. A heartfelt thank you to our patients and employees whose contributions have made this moment possible.

This LinkedIn page will no longer be active. Please follow the Lilly Oncology LinkedIn page for updates about STX-478 and stay tuned for an update about our spin company—exciting news will be coming soon!

 Scorpion Therapeutics patents new EGFR and HER2 inhibitors for cancer 

Eli Lilly Taps High-Grade Market to Fund Cancer Drug Purchase - Bloomberg.com

03/8/2022 Press Release Scorpion Therapeutics To Present Mutant-selective PI3Kα Program At AACR Annual Meeting 2022 Read More

 Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program 

 COMBINATION THERAPY FOR CANCER TREATMENT 

 The Week’s 10 Biggest Funding Rounds: Cardurion Pharmaceuticals And Human Interest Nab Largest Raises 


      
        




    07/29/2021

    

      
      Up And Down The Ladder: The Latest Comings And Goings
      Read More
    

Chutes & Ladders—GlaxoSmithKline's oncology head leaves for biotech Scorpion Therapeutics - Fierce Biotech

 Lilly takes a nibble at Scorpion program 


      
        




    07/16/2024

    

      
      Scorpion raises $150M with sights on the next wave of targeted therapies
      Read More
    

Scorpion’s CEO Axel Hoos, CMO bite the dust as oncology biotech brings in new leadership - Fierce Biotech


      
        




    01/12/2021

    

      
      Gary Glick, Keith Flaherty Now Have $270m To Realize Their Vision For Precision Oncology 2.0™ — We’ll Just Have To Wait For The Details
      Read More
    

Lilly catches Relay in PI3Ka race via Scorpion acquisition - biocentury.com


      
        




    07/16/2024

    

      
      Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline
      Read More
    

 Lilly reports full Q4 2024 financial results and provides 2025 guidance 


              DrugMap: A quantitative pan-cancer analysis of cysteine ligandability
            

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors - Business Wire

Odyssey starts journey with $218M for 7 assets across cancer, inflammation with IFM, Scorpion founder at the helm - Fierce Biotech

Eli Lilly Steals the Spotlight at JPM 2025 with $2.5 Billion Power Move Acquisition - geneonline.com

Former CEO of IFM Therapeutics launches new precision medicine startup with $108M - The Business Journals

 Boston Therapeutics rakes in $150m Series C 

10/10/2023 Press Release Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer Read More


      
        




    10/31/2022

    

      
      Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations
      Read More
    

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer - PR Newswire

Scorpion Therapeutics Raises $150M in Series C Financing - FinSMEs

Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn - Financial Times

 Most-Active US Investors In July: Andreessen Horowitz Led Cool Month 

 Health Care Climbs Amid Deal Activity - Health Care Roundup 

 Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program 

 Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs 

09/15/2024 Press Release Scorpion Therapeutics Presents Initial Clinical Data from Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024 Read More

 Scorpion Therapeutics to Present at Jefferies Healthcare Conference 

Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer | Journal of Medicinal Chemistry - ACS Publications

02/25/2021 Press Release Scorpion Therapeutics Announces Leadership Change Read More


      
        




    09/14/2024

    

      
      Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche
      Read More
    

 Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline 

We are pleased to share clinical program updates for our mutant-selective PI3Ka inhibitor STX-478 that underscore our commitment to advancing precision oncology.

At #SABCS24, we are presenting updated data from our Phase 1/2 study of STX-478. The results highlight robust PI3Kα pathway inhibition, favorable safety, and a clear dose-response relationship. These findings reinforce STX-478’s potential to transform outcomes for patients with a variety of solid tumors.

Additionally, we have entered into a new clinical trial collaboration with #Pfizer to evaluate Pfizer’s investigative selective-CDK4 inhibitor, in combination with STX-478 and fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer in the frontline metastatic setting.

Together with our partners, we are dedicated to shaping the future of cancer therapy by delivering innovative, targeted solutions for those who need them most. Learn more: https://bit.ly/4fbaw13  


      
        




    07/07/2021

    

      
      GSK’s Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
      Read More
    

Lilly nets Scorpion cancer drug in $2.5bn licensing deal - pharmaphorum


      
        




    07/07/2021

    

      
      GSK Oncology Exec Hoos Heads Back To Biotech As CEO Of Scorpion Therapeutics
      Read More
    

Scorpion Therapeutics

Business:

Drug notes:

About: